Hematologie Studies regio Leiden/Den Haag

Waar open

SCT + virale reactivatie

Indicatie: SCT + CMV / EBV / AdV infection
Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial
Open in: LUMC

B-cell Non-Hodgkin Lymphoma

Indicatie: Arm 1: 1e lijn DLBCL, IPI≥3, epcoritamab + RCHOP  
Arm 2: 2e lijn FL, epcoritamab + lenalidomide + rituximab  
Arm 3: 1e lijn FL, epcoritamab + bendamustine + rutixumab  
Arm 4: 2e lijn DLBCL, epcoritamab + RDHAX/C  
Arm 5: ≥2e lijn DLBCL, epcoritamab + GemOx
Studie:GENMAB GCT3013-02
A multicenter, open-label, non-randomized, Phase 1b/2 study to evaluate the safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia
Open in: LUMC


Indicatie: 1e lijn
Studie:HOVON 146
A phase II trial; Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults.
Open in: HAGA


Indicatie: 1e lijn CLL >=18 jaar
Studie:HOVON 158
First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial)
Open in: HAGA

Allogene Stamceltransplantaties

Indicatie: AML, leeftijd 40-60 jaar
Individualized dosing of fludarabine during innate allo SCT:
A randomized phase II study
Open in: LUMC

PTLD (ongeacht EBV status)

Indicatie: Biobanking voor MRD in combinatie met PET-scan monitoring bij Rituximab monotherapie en bij onvoldoende response RCHOP
Response assessment in post-transplant lymphoproliferative disorder with 18F-FDG-PET/CT and minimal residual disease monitoring, a multicenter multinational feasibility study
Open in: LUMC

Burkitt Lymfoom

Indicatie: 1e lijn
Studie:HOVON 127
Randomized phase II study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed
high risk Burkitt lymphoma
Open in: HAGA

Folliculair Lymfoom

Indicatie: 1e lijn, Fase 3 studie, randomizatie rituximab+ibrutinib vs R-placebo, ≥70y, of 60-69y met WHO=2 of eGFR 30-59 ml/min
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
Open in: LUMC

Multiple Myeloom

Indicatie: 1. Recidief myeloom, >=18 jaar, volgens IMWG criteria en binnen 12 maanden na laatste therapie  2. >=3 lijnen eerdere therapie, waaronder PI (>=2 cycli of 2 maanden therapie) en IMiD (>=2 cycli of 2 maanden therapie) en >= 1 cyclus voor iedere therapie Of Ziekte dubbel refractair op PI en IMiD 3. Meetbare ziekte (IgG M-proteine >=10 g/l, non-IgG M-proteine >= 5 g/l of vrije lichte keten myeloom met FLC >= 100 mg/l + abnormale FLC ratio
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
Open in: LUMC

Mantel cel lymfoom met TP53 mutatie

Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
Open in: LUMC
Totaal: 25     Volgende >>    Totaaloverzicht